Kornimate/medical-research-clean huggingface dataset:
cefazolin subcutaneous microdialysis in morbidly obese patients

Conditions: Morbid Obesity

Summary: the investigators hypothesize that cefazolin perfusion to subcutaneous adipose tissue is reduced in morbidly obese patients. the primary objective of this exploratory pilot study is therefore to investigate target site (subcutaneous adipose tissue) penetration of cefazolin in morbidly obese patients and non-obese patients. the investigators aim to examine whether and how cefazolin plasma concentrations are predictive of subcutaneous (target) cefazolin concentrations. possible factors of influence on the distribution of cefazolin (tissue perfusion, body weight, distribution of adipose tissue, other) will be identified.


Eligibility criteria:
inclusion criteria: * body mass index \> 40 kg/m2 * bmi between 20-25 * undergoing laparoscopic gastric banding, or bypass surgery or sleeve gastrectomy (see population description for surgery type of the non-obese group) * 21-60 years old * american society of anaesthesiologists (asa) physical status ii to iii exclusion criteria: * pregnancy * breastfeeding * known allergy for cefazolin/nadroparin * known ejection fraction of \< 35% * renal insufficiency

Keywords: cefazolin microdialysis morbid obesity pharmacokinetics
the application of impulse oscillometry on the diagnosis of acos,asthma and copd.

Conditions: Asthma-COPD Overlap Syndrome; Asthma; COPD; Diagnoses Disease

Summary: to assess the utility of impulse oscillometry on a differential diagnosis among the patients with acos,asthma and copd over age 40.

acos,asthma and copd are prevalent diseases with similar manifestations and different type airway impairments. the differential diagnosis is not easy because the patients always complain of the similar symptoms and are not able to complete spirometry well. impulse oscillometry system (ios) is capable of identifying airway obstruction and reactions to bronchodilators by providing impedance data and curves. ios is also a patient-friendly and valuable tool with minimal demands on patient and requiring only passive cooperation. ios is a tool to measure lung function during tidal breathing. the output is a measure of respiratory impedance (zrs), which include the respiratory resistance (rrs) and respiratory reactance (xrs) measured over a range of frequencies (usually from 3 to 35 hz). the main objective of this study is to investigate the ability of ios to measure small airway disease by providing different impedance profiles for participants with acos,asthma and copd. another objective of this study is to investigate the differential ability to identify three diseases by measuring airway impedance and reactions to bronchodilators. first,participants completed the ios test.second,participants inhaled salbutamol for 200g 15 minutes to repeat the ios.the investigators collect these 2 data for analysis.

Eligibility criteria:
inclusion criteria: - 1.1 acos: 1. patient is older than 40 years old. 2. there are characteristics of bronchial asthma and copd. 3. there is a history of exposure to risk factors. 4. existence of persistent airflow limitation: after the application of bronchodilators, fev1/fvc\<0.7, and lung function proved reversible exhalation. 5. the existence of reversible airflow limitation: bronchial dilation test positive. 1.2asthma: 1)patient is older than 40 years old. 2)history of reversible respiratory symptoms. 3) non-smokers. 4)lung function:at least one time proved that the airflow limitation: bronchial dilation test positive. 5)previously diagnosed asthma. 1.3copd: 1. patient is older than 40 years old. 2. complaints about dyspnea, chronic cough or expectoration. 3. there is a history of exposure to risk factors. 4. existence of persistent airflow limitation: after the application of bronchodilators, fev1/fvc\<0.7. 5. the existence of irreversible airflow limitation: bronchial dilation test negative. exclusion criteria: - 2.1 combining other respiratory diseases that affect airflow,such as lung cancer, tuberculosis, pneumonia and bronchiectasis. 2.2 at the time doing lung function test, the factors that affect the airflow limitation are not stopped or just stopped with the time interval not long enough to meet the test standard. 2.3 using special accompanying medication. for example, patients with drugs such as glucocorticoid.
impact of fast-rotation coronary ct in patients undergoing aortic stenosis workup

Conditions: Coronary Stenosis; Aortic Valve Stenosis; Cardiovascular Diseases

Summary: this study aims to evaluate the clinical value of a novel ct gantry supporting a .23 second rotation time and systematically compare it with 0.23 second rotation time, in patients with clinically indicated aortic cta in the workup of aortic stenosis. patients will be randomly assigned .23 or .28 sec rotation time cta. coronary artery interpretability rates will be determined in both groups.

coronary artery analysis is an essential component of cardiac ct, but is often challenging without beta-blocker use. ct's technological advances are continuously evolving, paving the way for safer and more accurate diagnoses. part of these innovations is the development of faster rotation speeds (0.23 sec/rotation), which is expected to allow for heart rate-independent ccta. patients subjected to aortic stenosis workup routinely undergo invasive coronary angiography (ica) in the catheterization laboratory, voiding the need to control the heart rate at the time of cardiac ct because aortic valve measurements can be performed even at higher heart rate. still, cardiac ct in this context is performed with ecg-gating, and attempting to evaluate coronary arteries is possible without interfering with clinical decisions. also, the existing literature advocates the use of gantry rotation speeds of at least 0.5 sec/rotation; consequently, the use of 0.28 versus 0.23 sec/rotation for this study will comply with current guidelines and will have no detrimental impact on patient management. this study aims to evaluate coronary artery interpretability in patients subjected to cardiac ct for the anatomical assessment of aortic valve stenosis prior to endovascular (transcatheter aortic valve implantation \[tavi\]) or surgical therapy. patients will be enrolled after providing written, informed consent, and will be randomly assigned either to the test (0.23 sec rotation time) or control group (0.28 sec rotation). the participants concerned are not subjected to any additional invasive or stressful procedure compared with those undergoing aortic stenosis workup in clinical routine.

Eligibility criteria:
inclusion criteria: * subjected to cardiac ct due to known or suspected aortic valve stenosis exclusion criteria: * patients unable to hold their breath, deaf or visually impaired * estimated glomerular filtration rate (egfr) of \<30 ml/min * hemodynamic instability or cardiogenic shock, acute pulmonary edema, exacerbated chronic obstructive pulmonary disease, pregnant and breast-feeding women * patients with prior coronary artery bypass grafting (cabg) * patient incapable of discernment

Keywords: computed tomography angiography artifacts diagnostic imaging image processing, computer-assisted
psychiatric comorbidity

Conditions: Otorhinolaryngologic Diseases

Summary: the goals of this project are aimed at the following: 1. identifying psychiatric comorbidity in patients presenting to the hnscs clinic 1f and duke otolaryngology of raleigh clinic using the validated assessment tool brief symptom inventory (bsi-18) and the patient control scale. the bsi-18 is an 18 question and patient control an 8 item tool that takes about four minutes to complete. 2. gathering data regarding patient satisfaction in new patients to the hnscs clinics via the cg-cahps visit survey. 3. examining relationships between psychiatric comorbidity and patient satisfaction. 4. examining relationships between psychiatric comorbidity and healthcare system use.

patients with multiple otolaryngology complaints experience psychosocial distress. this psychosocial distress can have an adverse effect on treatment outcomes for the primary complaint and on the overall patient experience. it can result in greater costs for more care that may not be best-directed. this has implications not only for the patients, but also for providers' quality metrics. data will be collected via surveys and a chart review. new patients at the duke clinic 1f and duke raleigh otolaryngology will be asked to complete the bsi-18, patient control scale, and disease specific outcome measure upon patient intake by the clinic nurse. the cg-cahps visit survey 2.1 will be completed at the conclusion of the clinical encounter. patient participation consists of these surveys on their initial visit only. the pi and/or a resident will conduct a chart review of these patients looking for history of psychiatric diagnoses and/or related prescriptions. patients who have psychiatric diagnoses and/or prescriptions in the chart will be considered to have their needs "met", in that they are receiving care. data regarding diagnoses and prescriptions will also be entered into redcap.

Eligibility criteria:
inclusion criteria: * age 18 or older * new patient appointment at duke clinic 1f or duke raleigh otolaryngology * ability to read, write, and understand english exclusion criteria: * less than 18 years old * unable to read, write, and understand english
psychiatric problems in chronic skin diseases

Conditions: Psoriasis; Acne; Vitiligo; Atopic Dermatitis; Pruritic Dermatitis

Summary: the purpose of this study is to investigate the prevalence of depression, anxiety, and sleep problems in patients with chronic skin diseases in dermatology clinics at the university of wisconsin hospital and clinics.


Eligibility criteria:
inclusion criteria: * subjects suffering from a chronic skin condition that has lasted over six months exclusion criteria: -
dahanca 30: a randomized non-inferiority trial of hypoxia-profile guided hypoxic modification of radiotherapy of hnscc.

Conditions: Head and Neck Squamous Cell Carcinoma; Radiotherapy; Hypoxic Modification; Hypoxia; Gene Profile, Gene Signature

Summary: hypoxic modification of radiotherapy with nimorazole has previously been shown to increase radiosensitivity in hypoxic head and neck squamous cell carcinomas (hnscc). in denmark, nimorazole is added the radiotherapy of most hnscc, as it has not previously been possible to discriminate more hypoxic tumours from less hypoxic tumours. a hypoxia gene profile has shown to discriminate between responders and non-responders to nimorazole. in dahanca 30, expected hypoxia profile guided non-responders are randomized to +/- nimorazole during radiotherapy.this in order to verify clinical use of the gene profile in selecting the relevant patients for hypoxic modification of radiotherapy with nimorazole.

hypoxic modification of radiotherapy with nimorazole has in the dahanca 5 trial been shown to increase radiosensitivity in hypoxic head and neck squamous cell carcinomas (hnscc). previously, it has not been possible to discriminate more hypoxic tumours from less hypoxic tumours. thus, nimorazole has been added the radiotherapy of most hnscc. recently, a hypoxia gene profile has been developed, that discriminate between more and less hypoxic tumours. the basis of the discrimination is the cumulated expression of 15 hypoxia responsive genes, quantified from the tumour biopsy. the profile has been validated on the independent dahanca 5 cohort. there was a significant effect of adding nimorazole to the radiotherapy of more hypoxic tumours as estimated with the gene profile, whereas there was no effect of adding nimorazole to the less hypoxic tumours. in a test for interaction, there was a significantly different response to nimorazole in the more hypoxic tumours compared to the less hypoxic tumours. in the dahanca 30 trial it is aimed to verify, that there is no benefit of supplying the radiotherapy of less hypoxic hnscc with nimorazole. thus, to explore whether it is possible to avoid the sideeffects of nimorazole without risk for the patient.

Eligibility criteria:
inclusion criteria: * head and neck squamous cell carcinoma with indication for hypoxic modification with nimorazole in accordance to the danish head and neck cancer guidelines (dahanca guidelines). * informed consent exclusion criteria: * previous or present malignant disease conflicting with the radiotherapy treatment or evaluation of the treatment. * participation in a conflicting protocol. * initiation of radiotherapy more than 3 weeks after inclusion
gallant 14 tesaglitazar vs. metformin and fenofibrate

Conditions: Type 2 Diabetes

Summary: this is a 24-week study to determine the lipid metabolic effects, safety, and tolerability of tesaglitazar compared with metformin and metformin in combination with fenofibrate in patients with type 2 diabetes and low high-density lipoprotein cholesterol (hdl-c). improvement in dyslipidemia will be evaluated. the study comprises a 2-week enrollment period, 6-week run-in and a 24-week randomized, double blind, parallel group, multi-center, active controlled (metformin with or without fenofibrate) treatment period and a 3-week follow-up. from visit 2 (run-in), all patients will receive a standardized dose of statin (rosuvastatin)


Eligibility criteria:
inclusion criteria: * provision of a written informed consent * men or women who are \>=18 years of age * female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control * diagnosed with type 2 diabetes * treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents exclusion criteria: * type 1 diabetes * new york heart association heart failure class iii or iv * treatment with chronic insulin * history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin) * history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) * creatinine levels above the normal range * received any investigational product in other clinical studies within 12 weeks * any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
role of positron emission tomography in detecting primary tumor in cases of metastases of unknown origin

Conditions: Metastasis of Unknown Origin

Summary: in most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. however, metastatic cancer of unknown primary site (muo) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. most common metastatic sites include the liver, lymph nodes, lungs, and bones. 18f-fluoro-2-deoxyglucose positron emission tomography (fdg-pet) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.


Eligibility criteria:
inclusion criteria: age \> 18 years patients with metastatic tumor. primary site was not detected with other radiological examinations both male and female. exclusion criteria: patients with known primary tumor pregnancy. age \< 18 years.
pharmacokinetic study on the administration of nadroparin dosing serum hgf in gynecological patients

Conditions: Genital Diseases, Female; Ovarian Neoplasms; Urogenital Neoplasms

Summary: the purpose of this study is to determine whether hgf serum concentration might be raised in vivo by administering nadroparin given with prophylactic purpose to gynecological patients.

the study consisted of two phases. in the first phase, the main hgf pharmacokinetic parameters were evaluated, comparing a group of six women treated with a single dose of calcic nadroparin to a control group of six untreated women. venous blood was drawn in both groups at 0, 30, 60, 90, 120, 150, 180, 240, 300, 360, 480 and 720 min. in the second phase, the hgf basal and maximum concentrations were measured in 17 women, undergoing one month of calcic nadroparin daily treatment. venous blood was drawn twice on day 1 (at 0 and 90 min after nadroparin administration), then once on days 8 and 28 (at 90 min after lmwh injection). calcic nadroparin was given subcutaneously at 2850 iu/0.3 ml anti-xa. patients' characteristics: in the first phase, 12 patients were enrolled, 6 treated with nadroparin for prophylactic anticoagulation and another 6 untreated as the control group. the six nadroparin-group patients were affected by benign pelvic gynaecologic diseases: three requiring laparoscopy and three laparotomy. in the control group, four were healthy women volunteers and two patients submitted to gynaecological pelvic surgery, but these women were not treated with prophylactic lmwh. in the second phase, 17 patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. all these patients underwent laparotomy; ten were affected by malignancy (ecoc) and seven by benign (uterine fibroma, ovarian cystadenoma) pelvic gynaecologic diseases.

Eligibility criteria:
inclusion criteria: * ≥ 18 years * ecog ps ≤ 1 * neutrophils ≥ 1500 l -1, platelets ≥ 150,000 l -1, creatinine 0.6 to 1.2 mg dl -1, total bilirubin ≤ 1 mg dl -1, ast ≤ 35 u l-1, alt ≤ 45 u l-1 for patients in the study group: high-moderate risk of deep vein thrombosis (for the administration of lmwh for 30 days after surgery) under general anesthesia\> 30 minutes, laparoscopy + at least one risk factor (age\> 40 years, obesity, varicose veins, previous episode of deep vein thrombosis and / or pulmonary thromboembolism, thrombophilia, malignancy, prolonged immobility, congestive heart failure) exclusion criteria: * severe liver and renal disease * diabetes * hyperlipidemia * marked osteoporosis * hiv infection * ongoing treatment with: immunosuppressive therapies, contraceptives, lipid-lowering drugs, nsaids, antiplatelet drugs, recent acute inflammatory or infectious (\<3 weeks) * a history of allergies, * drug possible confounding, caffeine, tobacco, ethanol (must not have been hired in the last 24 hours prior to sampling) * high risk of bleeding: peptic ulcer, history of hemorrhagic stroke, or bleeding disorders, severe hypertension, cerebral aneurysms, arteriovenous malformations, brain metastases
clinical trial in china

Conditions: Diseases of Aortic Valve; Aortic Regurgitation Disease

Summary: the purpose of this clinical study is to evaluate the effectiveness and safety of the transcatheter aortic valve system in the treatment of patients with severe aortic regurgitation disease who are at high or prohibitive surgical risk.

this study is a prospective, multicenter, single-arm, clinical study.

Eligibility criteria:
inclusion criteria: 1. age ≥ 65; 2. patients with symptomatic aortic valve regurgitation diseases, and new york heart association (nyha) ≥ ii; 3. subject must have society of thoracic surgeons (sts) score ≥8% or have been evaluated as inoperable by the surgical team \[defined as rate of death \>50% within 30 d post-surgery or accompanied with irreversible occasions of other factors prevent surgeries (such as heavily calcified (porcelain) ascending aorta, weakness, chest malformation, liver dysfunction, pulmonary dysfunction and so on ); (note: age of inoperable patients can be expanded to ≥ 50); 4. aortic valve anatomy is suitable for tavr evaluated by the investigators; 5. patients who can sign informed consent form, and are willing to accept relevant examinations and clinical follow-ups. exclusion criteria: 1. active endocarditis; 2. acute myocardial infarction or coronary revascularization occurred within 1 month before procedure; 3. cerebrovascular accident (cva) occurred within 30 days before procedure; 4. the echocardiogram indicates the presence of mass, thrombus or vegetation in left ventricle and left atrium; 5. hypertrophic obstructive cardiomyopathy; 6. other valve diseases that need interventions; 7. previous aortic valve implantation (mechanical or biological); 8. allergic to nickel-titanium alloys or contrast agents or cattle-originated products; 9. known allergy or contraindication to all anticoagulation, or anticoagulation can not be used during the tavr; 10. in presence one of the following (from selection to the day of procedure index): a other diseases that may shorten life expectancy to less than 12 months (recurrent or metastatic cancer, congestive heart failure); b drug abuse (such as cocaine, heroin and so on); c planned additional operations that may result in incompliance or data confusion; 11. stenosis of common carotid artery, internal carotid artery or vertebral artery \>70%; 12. severe left ventricular dysfunction, left ventricular ejection fraction (lvef) \<20%; 13. hepatic encephalopathy or acute active hepatitis; 14. receiving hemodialysis; 15. bleeding tendency or history of coagulopathy or refuse to receive transfusion; 16. active gastrointestinal (gi) ulcer or bleeding; 17. severe dementia; 18. patients who need emergency surgery for any reason; 19. patients are participating in other drugs or medical devices clinical trial; 20. pregnant or plan to be pregnant, or are taking estrogen or estrogen-like drugs (women suspected of pregnancy must have a negative serum or urine test for human villous gonadotropin prior to enrollment in the study); 21. other inappropriate occasions according to the investigators.
prospective comparison of ampicillin / amoxicillin versus ceftriaxone for the treatment of salmonella infections in aids patients

Conditions: HIV Infections; Salmonella Infections

Summary: to compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in aids patients.


Eligibility criteria:
exclusion criteria co-existing condition: patients with the following are excluded: * type i hypersensitivity to beta-lactam antibiotics. * not expected to survive 12 weeks. * in a coma or with other central nervous system (cns) impairment. patients with the following are excluded: * type i hypersensitivity to beta-lactam antibiotics. * not expected to survive 12 weeks. * in a coma or with other central nervous system (cns) impairment. prior medication: excluded within 48 hours of study entry: * treatment with an antibiotic active in vitro against salmonella. hiv infection, aids, or aids related complex (arc). * salmonella bacteremia or positive stool culture in patient with 3 or more stools per day.

Keywords: salmonella infections aids-related opportunistic infections acquired immunodeficiency syndrome amoxicillin ceftriaxone